Billion dollar deal centres on drug in stem cell transplantation
A new drug to treat severe hepatic veno-occlusive disease, a complication of cancer treatment involving hematopoietic stem cell transplantation, was the target for Jazz Pharmaceuticals, which has agreed to pay about a billion US dollars for Gentium.
Gentium, an Italy-based biopharma, won European Medicines Agency approval in October 2013 for defibrotide (Defitelio), its lead drug. The biopharmaceutical specialist focuses on serious, undertreated rare conditions.
The all-cash transaction has been approved by the boards of directors from both companies.
“We both are dedicated to bringing highly differentiated therapies to patients who have high unmet medical needs.”
Dr Khalid Islam, chairman and chief executive, Gentium.
Bruce Cozadd, chairman and chief executive, Jazz Pharmaceuticals.
Jazz Pharma to buy Italy’s Gentium for $1 bln (Reuter’s).
Summary of positive opinion for Defitelio (European Medicines Agency statement; PDF)
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide, Seminars in Thrombosis and Hemostasis, 2007 Jun; 33(4): 373-88.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.